Why Is NOVAVAX INC (NVAX) Stock Up Today?

NVAX stock rose 5.71% to $9.90 on Monday, driven by a combination of elevated call option volume and positive market sentiment. The stock opened slightly below the previous close but quickly reversed course, reaching a session high of $9.96 before settling near that level. The move follows recent regulatory developments involving the company’s vaccine portfolio.

What Happened

Novavax shares opened at $9.32, a modest 0.6% below the prior close, but quickly reversed course as call option volume surged above normal levels. The Fly noted that the directional bias in options activity was bullish, suggesting increased investor confidence. The stock’s rally was also supported by recent regulatory approvals for an updated formulation of Nuvaxovid, Novavax’s SARS-CoV-2 vaccine, targeting the XFG variant. This development comes amid broader market moves, as investors reacted to FDA approvals of updated vaccines from multiple manufacturers, including Novavax.

What The Data Shows

The stock’s intraday performance showed a strong reversal from its early session low of $9.19 to a high of $9.96. Trading volume of 1.6 million shares was three times the 3-month average, indicating heightened participation. Despite the rally, Novavax remains unprofitable, with a trailing twelve-month revenue decline of 61.6% and a net margin of -59.9%. The stock currently trades within its 52-week range of $6.20 to $11.97, having last printed a 52-week high on September 1, 2026. The 30-day average sentiment score of 60/100 improved to 64/100 in the past week, reflecting a gradual shift in investor perception.

What To Watch

Investors will look to upcoming developments in Novavax’s vaccine pipeline and broader market sentiment toward the biotech sector. No earnings report is scheduled in the near term. Coverage breadth remains limited, with only one story published in the last 36 hours.